BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30923997)

  • 1. Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies.
    Schuler E; Boughoufala S; Rautenberg C; Nachtkamp K; Dienst A; Fenk R; Haas R; Kondakci M; Germing U; Schroeder T; Kobbe G
    Ann Hematol; 2019 May; 98(5):1225-1235. PubMed ID: 30923997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies.
    de Jong G; Janssen JJWM; Biemond BJ; Zeerleder SS; Ossenkoppele GJ; Visser O; Nur E; Meijer E; Hazenberg MD
    Eur J Haematol; 2019 Nov; 103(5):491-499. PubMed ID: 31411761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
    Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
    Schroeder T; Rachlis E; Bug G; Stelljes M; Klein S; Steckel NK; Wolf D; Ringhoffer M; Czibere A; Nachtkamp K; Dienst A; Kondakci M; Stadler M; Platzbecker U; Uharek L; Luft T; Fenk R; Germing U; Bornhäuser M; Kröger N; Beelen DW; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):653-60. PubMed ID: 25540937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
    Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
    Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
    Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
    Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Salvage Chemotherapy Before Donor Lymphocyte Infusion in Patients With Relapse After Allogeneic Hematologic Stem Cell Transplantation.
    Aladag E; Goker H; Buyukasik Y; Demiroglu H
    Transplant Proc; 2021; 53(1):391-395. PubMed ID: 32665087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
    Sommer S; Cruijsen M; Claus R; Bertz H; Wäsch R; Marks R; Zeiser R; Bogatyreva L; Blijlevens NMA; May A; Duyster J; Huls G; van der Velden WJFM; Finke J; Lübbert M
    Leuk Res; 2018 Sep; 72():20-26. PubMed ID: 30064039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.
    Caldemeyer LE; Akard LP; Edwards JR; Tandra A; Wagenknecht DR; Dugan MJ
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1989-1997. PubMed ID: 28712934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.
    Merker M; Salzmann-Manrique E; Katzki V; Huenecke S; Bremm M; Bakhtiar S; Willasch A; Jarisch A; Soerensen J; Schulz A; Meisel R; Bug G; Bonig H; Klingebiel T; Bader P; Rettinger E
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1281-1292. PubMed ID: 30878607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schuler E; Wagner-Drouet EM; Ajib S; Bug G; Crysandt M; Dressler S; Hausmann A; Heidenreich D; Hirschbühl K; Hoepting M; Jost E; Kaivers J; Klein S; Koldehoff M; Kordelas L; Kriege O; Müller LP; Rautenberg C; Schaffrath J; Schmid C; Wolff D; Haas R; Bornhäuser M; Schroeder T; Kobbe G;
    Ann Hematol; 2021 Apr; 100(4):959-968. PubMed ID: 33191481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
    Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
    Horn B; Petrovic A; Wahlstrom J; Dvorak CC; Kong D; Hwang J; Expose-Spencer J; Gates M; Cowan MJ
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):729-37. PubMed ID: 25644958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double reduced-intensity allogeneic hematopoietic stem cell transplantation: a retrospective study from the SFGM-TC.
    Bay JO; Cabrespine A; Faucher C; Tabrizi R; Bordigoni P; Berceanu A; Coiteux V; Renaud M; Mialou V; Robin M; Kuentz M; Chevallier P; Dhédin N; Huynh A; Garban F; Witz F; Buzyn A; De Revel T; Galambrun C; Deconinck E; Contentin N; François S; Gratecos N; Blaise D; Michallet M;
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):250-6. PubMed ID: 21745455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
    Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis.
    Helbig G; Koclęga A; Woźniczka K; Kopera M; Kyrcz-Krzemień S
    Pathol Oncol Res; 2018 Jul; 24(3):469-475. PubMed ID: 28660547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
    Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
    Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.